Financially stable C4 Therapeutics (CCCC) is worth watching for patient investors, but current lack of definitive data poses ...

Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Free Report) have received an average rating of “Hold” from the five ...

C4 Therapeutics, Inc. ( (CCCC) ) has released its Q3 earnings. Here is a breakdown of the information C4 Therapeutics, Inc. presented to its ...

17:29 EDT C4 Therapeutics (CCCC) files to sell 4.87M shares of common stock for holders Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> ...

Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates by 12%. Looking ...

Oct. 15, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today ...

WATERTOWN, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that two abstracts ...